MET and renal cell carcinoma: C-MET signalling has been implicated in the generation and maintenance of stem cells within bone metastases from RCC and use of a c-Met inhibitor was demonstrated to reduce the development of bone metastases within murine models and decrease the circulating serum level of the osteotropic factors IL-11 and CCL20.